Zentalis Pharmaceuticals, Inc. $ZNTL is Tybourne Capital Management HK Ltd.’s 4th Largest Position

Tybourne Capital Management HK Ltd. cut its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 35.0% during the third quarter, HoldingsChannel reports. The fund owned 961,486 shares of the company’s stock after selling 516,666 shares during the quarter. Zentalis Pharmaceuticals comprises approximately 4.7% of Tybourne Capital Management HK Ltd.’s holdings, making the stock its 4th biggest position. Tybourne Capital Management HK Ltd.’s holdings in Zentalis Pharmaceuticals were worth $1,452,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC boosted its position in Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after purchasing an additional 8,236 shares during the last quarter. Corient Private Wealth LLC acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter worth about $41,000. State of Wyoming raised its stake in shares of Zentalis Pharmaceuticals by 63.4% during the 2nd quarter. State of Wyoming now owns 73,797 shares of the company’s stock worth $86,000 after purchasing an additional 28,621 shares in the last quarter. Man Group plc raised its stake in shares of Zentalis Pharmaceuticals by 302.3% during the 2nd quarter. Man Group plc now owns 406,344 shares of the company’s stock worth $471,000 after purchasing an additional 305,328 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Zentalis Pharmaceuticals by 145.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 173,484 shares of the company’s stock valued at $201,000 after buying an additional 102,661 shares during the last quarter.

Zentalis Pharmaceuticals Stock Up 0.4%

Shares of ZNTL stock opened at $2.40 on Tuesday. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.01 and a 12 month high of $3.95. The company has a market cap of $173.40 million, a PE ratio of -1.16 and a beta of 1.72. The business’s 50 day moving average is $2.10 and its two-hundred day moving average is $1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.12. As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Morgan Stanley dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 12th. Leerink Partners reissued a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.00.

Insiders Place Their Bets

In other news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the transaction, the insider directly owned 6,459,973 shares in the company, valued at approximately $8,591,764.09. The trade was a 53.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Group Walters acquired 6,459,973 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were acquired at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the transaction, the insider directly owned 13,509,973 shares in the company, valued at $16,211,967.60. The trade was a 91.63% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 7,503,096 shares of company stock valued at $9,982,878. Company insiders own 1.90% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.